Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial

Circulation Heart Failure 2026 Open access

Read full text
Authors: Ayodele Odutayo, Deepak L Bhatt, Vikas S. Sridhar, Michael Szarek, Christopher P Cannon, Lawrence A Leiter, Darren K. McGuire, Julia Breyer Lewis, Renato D. Lópes, Benjamin M. Scirica, Kausik K Ray, Michael J Davies
+7 more Phillip Lee Banks, Manon Girard, Subodh Verma, Jacob Allen Udell, Bertram Pitt, Philippe Gabríel Steg, David Z I Cherney
DOI: 10.1161/circheartfailure.125.013054
Cited by: 1
References: 26

Abstract

BACKGROUND: The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America heart failure (HF) classification incorporates cardiac biomarkers to identify early risk of HF. The HF stages may also guide the prognosis and management of cardiovascular and kidney-related events. METHODS: SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) was a randomized trial in diabetes with kidney disease comparing sotagliflozin versus placebo on cardiovascular death, HF hospitalizations, and urgent HF visits. SCORED participants were grouped by HF stage post hoc. Stage A: no HF, normal biomarkers (NT-proBNP [N-terminal pro-B-type natriuretic peptide]

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Heart Failure Treatment and Management

Publication details

Journal / source
Circulation Heart Failure
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
19
Issue
3
Pages
e013054–e013054
Publication date
22 January 2026
Language
EN